Infant Bacterial (Sweden) Today
| IBT-B Stock | SEK 39.00 0.80 2.09% |
Performance0 of 100
| Odds Of DistressOver 64
|
Infant Bacterial is selling for under 39.00 as of the 26th of November 2024; that is 2.09% up since the beginning of the trading day. The stock's lowest day price was 38.6. Infant Bacterial has more than 64 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Infant Bacterial Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 5th of July 2023 and ending today, the 26th of November 2024. Click here to learn more.
Infant Bacterial Therapeutics AB , a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company was founded in 2013 and is based in Stockholm, Sweden. Infant Bacterial is traded on Stockholm Stock Exchange in Sweden. The company has 10.85 M outstanding shares. More on Infant Bacterial Therapeutics
Moving against Infant Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Infant Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Infant Bacterial's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Infant Bacterial or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Infant Bacterial Therapeutics (IBT-B) is traded on Stockholm Exchange in Sweden and employs 5 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 560.25 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Infant Bacterial's market, we take the total number of its shares issued and multiply it by Infant Bacterial's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Infant Bacterial operates under Healthcare sector and is part of Biotechnology industry. The entity has 10.85 M outstanding shares.
Infant Bacterial Therapeutics has accumulated about 386.75 M in cash with (55.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 48.15, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Infant Bacterial Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Infant Bacterial is kr560.25 Million. 30% of Infant Bacterial outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Infant Ownership Details
Infant Bacterial Risk Profiles
Although Infant Bacterial's alpha and beta are two of the key measurements used to evaluate Infant Bacterial's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.91 | |||
| Standard Deviation | 8.81 | |||
| Variance | 77.65 | |||
| Risk Adjusted Performance | (0.06) |
Infant Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Infant Bacterial without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Money Managers Now
Money ManagersScreen money managers from public funds and ETFs managed around the world |
| All Next | Launch Module |
Infant Bacterial Corporate Management
Elected by the shareholders, the Infant Bacterial's board of directors comprises two types of representatives: Infant Bacterial inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Infant. The board's role is to monitor Infant Bacterial's management team and ensure that shareholders' interests are well served. Infant Bacterial's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Infant Bacterial's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anders Kronstrm | Chief Officer | Profile | |
| Maria Ekdahl | Chief Officer | Profile | |
| Robert Molander | Chief Officer | Profile | |
| Pr MD | Chief Officer | Profile | |
| Staffan Stromberg | Chief Officer | Profile |
Additional Tools for Infant Stock Analysis
When running Infant Bacterial's price analysis, check to measure Infant Bacterial's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Infant Bacterial is operating at the current time. Most of Infant Bacterial's value examination focuses on studying past and present price action to predict the probability of Infant Bacterial's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Infant Bacterial's price. Additionally, you may evaluate how the addition of Infant Bacterial to your portfolios can decrease your overall portfolio volatility.